Qiming Wang

机构：Henan Cancer Hospital · ORCID：0000-0002-7813-2885

发表论文 55 篇 · 总被引 1489 次 · h-index 16

代表论文

• Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (2024 · New England Journal of Medicine · 被引 302)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
• Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer (2024 · Cancer Cell · 被引 22)
• ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. (2025 · Journal of Clinical Oncology · 被引 16)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)